The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis

Acta Reumatologica Portuguesa

Volumn 2015, Issue 3, 2015, Pages 262-267

  Ersozlu Bozkirli E D ^a   Keşkek, Şakir Özgür ^b   Bozkirli, E ^a   Yucel A E ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Ankylosing spondylitis; Depression; Infliximab

Indexed keywords

INFLIXIMAB;

ADULT; COMPLICATION; DEPRESSION; FEMALE; HUMAN; MALE; PROSPECTIVE STUDY; SPONDYLITIS, ANKYLOSING;

ADULT; DEPRESSION; FEMALE; HUMANS; INFLIXIMAB; MALE; PROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING;

EID: 84948777740     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hellmann DB, Imboden JB. Blood Disorders. In: Papadakis MA, McPhee SJ, ed Current Medical Diagnosis and Treatment. New York: Mc Graw Hill; 2014: 822-823.
2. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379-1390.
3. Lim HJ, Lim HS, Lee MS. Relationship between self-efficacy and exercise duration in patients with ankylosing spondylitis.Clin Rheumatol 2005; 24(4):442-443.
4. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370(9590): 851-858.
5. Kırım S, Kekek Ö, Köksal F, Haydardedeolu FE, Bozkırlı E, Toledano Y. Depression in patients with euthyroid chronic autoimmune thyroiditis. Endocr J 2012; 59: 705-708.
6. Kekek Ö, Haydardedeolu FE, Kırım S, et al. Which increases depressive symptoms in obese patients, hypertension or diabetes? Qscience Connect 2013. http://dx.doi.org/10.5339/connect. 2013.9.
7. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
8. Ndreu JL, Otón T, Sanz J. [Anti-TNF therapy in ankylosing spondylitis: symptom control and structural damage modification]. Reumatol Clin 2011; 7(1): 51-55. doi: 10.1016/j.reuma. 2009.03.007.
9. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for anklosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27(4): 361-368.
10. Garret S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Anklosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286-2291.
11. Calin A, Garret S, Whitelock H, et al. A new approach to defining functional ability in anklosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21(12): 2281-2285.
12. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS--endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24.
13. Tegin B. Cognitive impairments in depression: an investigation based on Beck's Model. Ankara, Turkey: Hacettepe University; 1980.
14. Hisli N. Validity and reliability of Beck Depression Inventory among university students. Turk J Psychol 1989; 7: 3-13.
15. Beck AT, Ward CH. "An inventory for measuring depression". Arch Gen Psychiatry 1961; 4(6): 561-571.
16. Eisendrath SJ, Lichtmacher JE. Mood Disorders. In: Papadakis MA, McPhee SJ, ed Current Medical Diagnosis and Treatment. New York: Mc Graw Hill; 2014: 1023-1024.
17. Li Y, Zhang S, Zhu J, Du X, Huang F. Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. Arthritis Res Ther 2012; 14(5): R215. [Epub ahead of print].
18. Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF- antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 2012; 32(2): 323-330. doi: 10.1007/s00296-010-1616-x.
19. Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) 2006; 45(10): 1288-1293.
20. Ortancil O, Konuk N, May H, Sanli A, Ozturk D, Ankarali H. Psychological status and patient-assessed health instruments in ankylosing spondylitis. J Clin Rheumatol 2010; 16(7): 313-316. doi: 10.1097/RHU.0b013e3181f3bfba.
21. Arısoy O, Bes C, Cifci C, Sercan M, Soy M. The effect of TNFalpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation. Rheumatol Int 2013; 33(7): 1855-1864. doi: 10.1007/s00296-013-2671-x.
22. Taurog JD. The Spondyloarthritides. In: Longo DL, ed Harrison's principles of internal medicine. New York: Mc Graw Hill; 2012: 2777.
23. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
24. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429-433.
25. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004; 19(6): 397-403.
26. Uguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009; 63(1): 50-55. doi: 10.1111/j.1440-1819.2008.01905.x.
27. Iglesias M, Barreiro de Acosta M, Vázquez I, et al. Psychological impact of Crohn's disease on patients in remission: anxiety and depression risks. Rev Esp Enferm Dig 2009; 101(4): 249-257.